Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic Portfolio Corporate NewsBy adminNovember 28, 2023
Details Standalone financial statements for the period ended 30 September 2023Standalone Financial StatementsBy adminNovember 14, 2023
Details Consolidated financial statements for the period ended 30 September 2023Consolidated Financial Statements resultsBy adminNovember 14, 2023
